CPD · Women 50+
Meridian
Language
Track
OverviewCurriculumEvidence graderLibraryMy progress
Overall completion0%
Modules · Primary care
01Reproductive Aging and the STRAW+10 Map02Vasomotor Symptoms: KNDy Neurons and the Thermoneutral Zone03Menopausal Hormone Therapy: Reading WHI Properly04Prescribing MHT: Routes, Regimens and Progestogen Choice05Non-Hormonal Therapy for Vasomotor Symptoms06Genitourinary Syndrome of Menopause07Bone Loss, Fracture Risk and the Sarcopenia Overlap08Cardiometabolic Change After 5009Brain Fog, Mood and Sleep10The Menopause Consultation: Equity, Risk Communication and Review

Educational content for registered health professionals. Not a substitute for current national guidance, product licences or clinical judgement.

Back to module
Evidence summary

Cardiometabolic Change After 50

Meridian · Women's Health After 50Generated: 4 August 2026

08Cardiometabolic Change After 50

Body composition, lipids and blood pressure shift with the transition — independently of ageing.

Key takeaways

  • —SWAN showed visceral fat rises sharply across the transition even when body weight is stable — waist measurement outperforms weight for tracking.
  • —Age at menopause under 45 is an independent cardiovascular risk factor and belongs in the risk conversation.
  • —Adverse pregnancy outcomes decades earlier are recognised risk enhancers in current prevention guidelines and are almost never recorded.
  • —MHT is not indicated for cardiovascular prevention — but neither is it a cardiovascular contraindication in appropriately selected early postmenopausal women.
  • —Statin under-prescription and under-titration in women is a persistent, measurable disparity.

Graded claims

B

Visceral adiposity increases across the menopause transition independent of ageing

Supported in defined populationsSWAN and longitudinal imaging cohorts.

B

Menopause before age 45 is an independent cardiovascular risk factor

Supported in defined populationsConsistent large cohort and meta-analytic data.

B

Adverse pregnancy outcomes are cardiovascular risk enhancers

Supported in defined populationsEndorsed in ACC/AHA and ESC prevention guidelines.

F

MHT should be prescribed for primary prevention of coronary disease

Refuted or actively misleadingNot an indication in any major guideline.

B

Transdermal estradiol has a neutral effect on triglycerides compared with oral

Supported in defined populationsPharmacological first-pass effect, consistently demonstrated.

A

Statins are equally effective for secondary prevention in women and men

Established — RCT / guideline-gradeCTT collaboration individual-participant meta-analysis.

Supporting references

  1. Menopause Transition and Cardiovascular Disease Risk: AHA Scientific Statement — El Khoudary et al., Circulation 2020 https://pubmed.ncbi.nlm.nih.gov/33179545/
  2. Adiposity changes across the menopause transition (SWAN) — Greendale et al., JCI Insight 2019 https://pubmed.ncbi.nlm.nih.gov/30843880/
Educational summary for registered health professionals. Grades reflect strength of evidence at the time of writing and do not replace current national guidance, product licences or clinical judgement.